An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs GSK 189254 (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Jan 2011 Additional trial locations (Austria, Netherlands, Spain) identified as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Aug 2008 to Nov 2006 as reported by Clinicaltrials.gov.